Clinical trial
Phase 1-2 Trial Evaluating Metronomic Chemotherapy in Patients With a Relapsed or Refractory Wilms Tumor
NCT05384821 is registered in ClinicalTrials.gov with Centre Oscar Lambret as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 1-2 Trial Evaluating Metronomic Chemotherapy in Patients With a Relapsed or Refractory Wilms Tumor
- Lead sponsor
- Centre Oscar Lambret
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- September 14, 2022
- Completion date
- October 31, 2028
- Enrollment
- 28 (estimated)
- Sites
- 18
Conditions
As the registry lists them; a condition with its own page is linked.